8% Off
Gadoscan287 mg/ml
Popular Pharmaceuticals Ltd.
৳915.40
Add to cart
Generic medicine
Gadodiamide: Brands, Price & Uses in Bangladesh
Gadodiamide is a gadolinium-based contrast agent (GBCA) indicated for intravenous use in magnetic resonance imaging (MRI) to provide contrast enhancement that aids visualization of lesions and…
About Gadodiamide
Indications of Gadodiamide
Gadodiamide is a gadolinium-based contrast agent (GBCA) indicated for intravenous use in magnetic resonance imaging (MRI) to provide contrast enhancement that aids visualization of lesions and structures with abnormal vascularity or blood-brain-barrier disruption.
Established / FDA-approved indications
- Central nervous system (CNS) imaging: Contrast enhancement during cranial and spinal MRI in adult and pediatric patients (including term neonates) to visualize lesions with abnormal vascularity or blood-brain-barrier disruption.
- Extracranial/extraspinal (body) imaging: Contrast enhancement during MRI of the head and neck and body (including but not limited to the abdomen, pelvis, breast, and musculoskeletal soft tissue) in adults and pediatric patients 2 years of age and older, to visualize lesions with abnormal vascularity.
Guideline-supported / commonly performed uses
- Contrast-enhanced MR angiography (MRA) to assess vascular anatomy and patency, an established but sometimes off-label application depending on the specific vascular bed.
Note: Gadodiamide is a diagnostic imaging agent, not a therapeutic drug — it has no treatment indication and is used solely to improve diagnostic image quality.
Dosage & Administration of Gadodiamide
Dosage of Gadodiamide is calculated by body weight and administered as a single intravenous bolus injection; see the Dosage and Administration sections for indication-specific amounts and injection technique.
| Indication | Population | Recommended Dose |
|---|---|---|
| CNS (brain/spine) MRI | Adults | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadodiamide; a repeat dose immediately following the first may be used if clinically needed |
| CNS MRI | Pediatric (including term neonates) | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadodiamide |
| Body/extracranial MRI | Adults | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadodiamide |
| Body/extracranial MRI | Pediatric ≥ 2 years | 0.1 mmol/kg (0.2 mL/kg) IV bolus of Gadodiamide |
Use the lowest dose of Gadodiamide necessary to obtain adequate imaging, particularly in patients with reduced renal function (see Precautions and Warnings).
Side Effects of Gadodiamide
| Frequency | Effects |
|---|---|
| Common | Headache, nausea, injection-site coldness/pain, dizziness, transient taste disturbance, sensation of warmth or flushing |
| Less common | Vomiting, paresthesia, pruritus, rash, hypotension |
| Serious (rare) | Anaphylactoid/hypersensitivity reactions (bronchospasm, facial/laryngeal edema, severe hypotension, cardiac arrest), nephrogenic systemic fibrosis in at-risk patients with severe renal impairment |
Seek urgent medical attention for any signs of a severe reaction (difficulty breathing, swelling of the face or throat, severe rash, chest pain) after Gadodiamide administration.
Contraindications of Gadodiamide
Gadodiamide is contraindicated in patients with a history of a prior severe hypersensitivity (including anaphylactic) reaction to Gadodiamide or its components.
No other absolute contraindication is established for Gadodiamide; severe renal impairment is a major precaution (a risk factor for nephrogenic systemic fibrosis) requiring careful risk-benefit assessment rather than an absolute prohibition — see Precautions and Warnings.
Frequently Asked Questions about Gadodiamide
What is Gadodiamide used for?
Gadodiamide is not a treatment; it is a gadolinium-based contrast agent injected before or during an MRI scan to make certain tissues, lesions, and blood vessels show up more clearly, helping doctors diagnose conditions of the brain, spine, and body.
Is Gadodiamide safe for people with kidney problems?
Gadodiamide carries a boxed warning: in patients with severe kidney impairment or acute kidney injury, it can rarely cause a serious condition called nephrogenic systemic fibrosis (NSF). Anyone with known kidney disease should have their kidney function checked before receiving Gadodiamide, and doctors use the lowest effective dose and avoid repeated doses in this group.
Can Gadodiamide be used during pregnancy or breastfeeding?
Gadodiamide should be used during pregnancy only if the scan information is essential and cannot wait until after delivery or be obtained without contrast, since it crosses the placenta. Only a tiny amount of Gadodiamide passes into breast milk, and many guidelines consider it acceptable to continue breastfeeding as normal after Gadodiamide, though you should confirm with your doctor.
What are the common side effects of Gadodiamide?
Most people tolerate Gadodiamide well. The most common effects are mild, including headache, nausea, a cold or briefly painful sensation at the injection site, dizziness, or a temporary odd taste. Serious allergic reactions to Gadodiamide are rare but require immediate medical attention if they occur.
Who should not receive Gadodiamide?
Gadodiamide should not be given to anyone who has had a previous severe allergic (anaphylactic) reaction to Gadodiamide. It also requires caution and careful risk assessment in patients with severe kidney impairment because of the risk of nephrogenic systemic fibrosis.
Is Gadodiamide given as a pill?
No. Gadodiamide is only given as an intravenous injection by a physician or trained radiology staff immediately before or during an MRI scan; it is never taken orally or self-administered at home.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.